Paper10898685
Antimycobacterial activities of novel levofloxacin analogues.
Kawakami K and 5 others. Antimicrob Agents Chemother, 2000. Cited by 8 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Antimycobacterial activities of novel levofloxacin analogues. Papers, record 10898685. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10898685
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Infective Agents | Major topic |
| Levofloxacin | Major topic |
| Mycobacterium avium | Major topic |
| Mycobacterium tuberculosis | Major topic |
| Ofloxacin | Major topic |
| Humans | |
| Microbial Sensitivity Tests | |
| Structure-Activity Relationship |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2,183,714 | Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/2183714 | PubMed |
| 2 | 2,334,166 | Influence of N substitution on antimycobacterial activity of ciprofloxacin. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/2334166 | PubMed |
| 3 | 1,952,872 | In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. | Antimicrob Agents Chemother | 1991 | https://conductscience.org/library/papers/1952872 | PubMed |
| 4 | 1,660,089 | [Antimycobacterial activities of a new quinolone, sparfloxacin]. | Kekkaku | 1991 | https://conductscience.org/library/papers/1660089 | PubMed |
| 5 | 1,727,901 | Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States. | J Infect Dis | 1992 | https://conductscience.org/library/papers/1727901 | PubMed |
| 6 | 1,771,676 | Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria. | Tubercle | 1991 | https://conductscience.org/library/papers/1771676 | PubMed |
| 7 | 1,663,283 | In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. | Tubercle | 1991 | https://conductscience.org/library/papers/1663283 | PubMed |
| 8 | 1,600,578 | Tuberculosis: a global overview of the situation today. | Bull World Health Organ | 1992 | https://conductscience.org/library/papers/1600578 | PubMed |
| 9 | 1,296,597 | Multidrug-resistant tuberculosis. | Ann Intern Med | 1992 | https://conductscience.org/library/papers/1296597 | PubMed |
| 10 | 8,392,307 | Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8392307 | PubMed |
| 11 | 8,350,889 | Treatment of multidrug-resistant tuberculosis. | N Engl J Med | 1993 | https://conductscience.org/library/papers/8350889 | PubMed |
| 12 | 8,230,135 | Fluorocyclopropyl quinolones. 1. Synthesis and structure-activity relationships of 1-(2-fluorocyclopropyl)-3-pyridonecarboxylic acid antibacterial agents. | J Med Chem | 1993 | https://conductscience.org/library/papers/8230135 | PubMed |
| 13 | 8,239,587 | Anti-Mycobacterium avium activity of quinolones: in vitro activities. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8239587 | PubMed |
| 14 | 8,239,588 | Anti-Mycobacterium avium activity of quinolones: structure-activity relationship studies. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8239588 | PubMed |
| 15 | 8,046,808 | Epidemiology of tuberculosis in the United States, 1985 through 1992. | JAMA | 1994 | https://conductscience.org/library/papers/8046808 | PubMed |
| 16 | 8,067,756 | Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/8067756 | PubMed |
| 17 | 7,944,836 | Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. | Arch Intern Med | 1994 | https://conductscience.org/library/papers/7944836 | PubMed |
| 18 | 7,829,409 | In-vitro activity of quinolones and macrolides against mycobacteria. | J Antimicrob Chemother | 1994 | https://conductscience.org/library/papers/7829409 | PubMed |
| 19 | 7,695,276 | In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. | Antimicrob Agents Chemother | 1994 | https://conductscience.org/library/papers/7695276 | PubMed |
| 20 | 7,778,959 | National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. | Arch Intern Med | 1995 | https://conductscience.org/library/papers/7778959 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,423,347 | Secondary Metabolites from a New Antibiotic-Producing Endophytic Streptomyces Isolate Inhibited Pathogenic and Multidrug-Resistant Mycobacterium tuberculosis Strains. | Trop Med Infect Dis | 2025 | https://conductscience.org/library/papers/40423347 | PubMed |
| 12,384,378 | Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12384378 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10898685
GET https://conductscience.org/api/papers/v1/10898685/references?page=2